WO1999001195A1 - Removal of biologically active agents - Google Patents
Removal of biologically active agents Download PDFInfo
- Publication number
- WO1999001195A1 WO1999001195A1 PCT/US1998/013145 US9813145W WO9901195A1 WO 1999001195 A1 WO1999001195 A1 WO 1999001195A1 US 9813145 W US9813145 W US 9813145W WO 9901195 A1 WO9901195 A1 WO 9901195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biologically active
- active agent
- body fluid
- substrate
- polyalkylene imine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3675—Deactivation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3291—Characterised by the shape of the carrier, the coating or the obtained coated product
Definitions
- the invention relates to removing biologically active agents from liquids.
- Heparin for example, is routinely added to blood as an anticoagulant in applications where the blood is to be transferred through extracorporeal circuits such as those employed in hemodialysis and cardiovascular surgery.
- the presence of heparin in the blood creates a significant risk of hemorrhaging.
- the invention features an apparatus for removing a biologically active agent (e.g., heparin) from body fluid that includes an inlet for receiving body fluid, a substrate that includes the reaction product of a substantially water insoluble polymer and a polyalkylene imine, the polyalkylene imine being in a form capable of binding a biologically active agent in the body fluid, and an outlet through which the body fluid flows following contact with the substrate.
- a biologically active agent e.g., heparin
- the invention also features a method for removing a biologically active agent from body fluid using this apparatus.
- Bioly active agents which can be removed include negatively charged materials. Specific examples of biologically active agents that can be removed include heparin, heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, derivatives thereof, and combinations thereof.
- the preferred polyalkylene imine is polyethylene imine.
- Preferred substantially water insoluble polymers include functional groups such as ester groups that are capable of forming a covalent bond with the polyalkylene imine.
- Specific examples include (a) the reaction product of an alkyl acrylate and an alkyl methacrylate, b) the reaction product of an alkyl acrylate, an alkyl methacrylate, and a hydroxy alkyl acrylate, and (c) the reaction product of an alkyl methacrylate, an alkyl acrylate, and N-vinyl pyrrolidone (e.g., the reaction product of methyl methacrylate, isooctyl acrylate, and N-vinyl pyrrolidone).
- the acrylate, methacrylate, and N-vinyl pyrrolidone may be provided in the form of monomers, oligomers, or a combination thereof.
- the apparatus further includes a conduit for transporting body fluid from a patient to the inlet and a conduit for transporting body fluid through the outlet to a patient.
- the apparatus is in fluid communication with a blood oxygenator.
- the apparatus is in fluid communication with a blood dialyzer.
- the apparatus may also be in the form of a syringe.
- the invention features an apparatus for removing a biologically active agent from body fluid that includes an inlet for receiving body fluid, a substrate that includes a polyalkylene imine immobilized thereon in a form capable of binding the biologically active agent, and an outlet through which the body fluid flows following contact with the substrate.
- the invention also features a method for removing a biologically active agent from body fluid using this apparatus.
- a “biologically active agent” is a material that, when in contact with a patient's blood, plasma, or other body fluids or tissues under physiological conditions, exhibits biological activity.
- a material such as heparin is
- biologically active in the sense that it acts as an anti-coagulant in the presence of blood.
- the invention provides a simple and effective means for removing biologically active agents such as heparin from body fluid.
- the process may be conducted in the presence of red blood cells.
- Fig. 1 is a perspective view of an apparatus for removing a biologically active agent according to one embodiment of the invention.
- Fig. 2 is a cross-sectional view taken along line A- A' of the apparatus shown in Fig. 1.
- Fig. 3 is a schematic view of the apparatus of Fig. 1 in fluid communication with an oxygenator.
- Fig. 4 is a perspective view of an apparatus for removing a biologically active agent according to a second embodiment of the invention.
- an apparatus 10 for removing a biologically active agent e.g., heparin
- body fluid featuring an inlet 12 for receiving a body fluid, a substrate 14, and an outlet 16 through which the body fluid flows following contact with substrate 14.
- Inlet 12 coupled to oxygenator 20 by tubing 24 is shown in Fig. 3.
- a pump (not shown) may be used to facilitate the flow of body fluid from oxygenator 20 to inlet 12.
- Outlet 16 is coupled to a patient by tubing 26.
- an apparatus 30 for removing a biologically active agent is shown in the form of a syringe.
- the apparatus 30 includes an inlet 36 for receiving a body fluid, a substrate 34, and an outlet 38 through which body fluid flows following contact with substrate 34.
- Inlet 36 is connected to needle 40 by a connecting portion 42.
- Outlet 38 is connected to cylinder 46 by connecting portion 44.
- Substrates 14 and 34 include a polyalkylene imine immobilized thereon in a form that is capable of binding a biologically active agent present in a body fluid.
- the biologically active agent preferably includes negatively charged groups. It may be an anti-thrombotic agent (e.g., a glycosaminoglycan (or a derivative thereof) such as heparin or a heparin derivative), an anti-microbial agent, a therapeutic agent (e.g., drug or growth factor), an enzyme, or a cell attachment protein.
- an anti-thrombotic agent e.g., a glycosaminoglycan (or a derivative thereof) such as heparin or a heparin derivative
- a therapeutic agent e.g., drug or growth factor
- an enzyme e.g., a cell attachment protein
- Other examples of suitable biologically active agents include heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, and derivatives thereof. More than one agent can be removed from body fluid.
- Suitable polyalkylene imines are those having an average molecular weight of between about 300 and 1
- the polyalkylene imine may be immobilized on a variety of substrates.
- any substrate on which polyethylene imine can be immobilized and which can pass a body fluid e.g., blood or plasma
- suitable substrates include woven fabrics, non-woven materials, foams, films, porous membranes, porous fibers, porous ceramics, metals, polymers, and beads.
- suitable polymer substrates include polypropylene, poly (vinyl chloride), poly (methyl methacrylate), polytetrafluoroethylene, polysulfone, polyethylene terephthalate, polycarbonate, polyethylene, polystyrene, and polyurethane.
- the substrate may take many forms, e.g., a cylindrical roll of woven fabric wound around a central mandrel and placed in an housing.
- a variety of processes may be used to immobilize the polyalkylene imine onto the surface of the substrate.
- One such process involves contacting the substrate with a polyalkylene imine, which will render the surface wettable and positively charged.
- the polyalkylene imine is preferably in the form of an aqueous solution, e.g., a 0.1% by weight solution of polyalkylene imine in water, when it is contacted with the substrate.
- the polyalkylene imine is then contacted with a polymeric anionic compound, thereby further increasing the wettability of the surface.
- polymeric anionic compounds include polygalacturonic acid and polyacrylic acid.
- the use of a polymeric anionic compound also allows the addition of a second polyalkylene imine (which may be the same as, or different from, the first polyalkylene imine) to the surface.
- the second polyalkylene imine binds to the polymeric anionic compound.
- the surface has been sequentially treated with three agents to create a primed surface: (1) first polyalkylene imine, (2) polymeric anionic compound, and (3) second polyalkylene imine.
- the sequence may be repeated as many times as necessary, the particular number of steps being selected by the particular application for which the treated article is intended. This process is further described in U.S. Patent No. 5,532,311 (Sirvio et al.), incorporated herein by reference.
- a second process for preparing a substrate having polyalkylene imine immobilized thereon involves coating the substrate with a priming solution that contains an organic solvent and the reaction product of a polyalkylene imine, such as polyethylene imine, and a water insoluble polymer, and then drying the substrate.
- the resulting primed surface of the substrate is coated with the reaction product of the polyalkylene imine and the water insoluble polymer.
- the solution may be coated on the substrate and dried as many times as is necessary to achieve the desired concentration of polyalkylene imine on the substrate.
- the particular amount of coating and concentration of polyalkylene imine on the substrate will depend upon the particular application for which the treated substrate is intended. This process is also described in co-pending, commonly assigned U.S. Patent Application No. entitled "Process For Modifying Surfaces Using The Reaction
- Preferred polyalkylene imine priming solutions include between about 0.1 to about 20% solids in a solution that includes between about 50 and about 99.9% organic solvent and up to about 50% water.
- the weight to weight ratio of substantially water insoluble polymer to polyalkylene imine is preferably in the range of between about 0.1:1 and about 10:1, more preferably about 4:1.
- Preferred substantially water insoluble polymers are those polymers that provide functional groups, e.g., ester groups, capable of forming a covalent bond with the amine groups of the polyalkylene imine while not interfering with the ability of the polyalkylene imine to bind to a biologically active agent.
- the substantially water insoluble polymer preferably is soluble in those organic solvents in which the polyalkylene imine is soluble.
- Suitable substantially water insoluble polymers include water insoluble acrylate-containing polymers such as, e.g., alkyl acrylate-alkyl methacrylate copolymers (e.g., copolymers of isooctyl acrylate and methyl methacrylate), alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers (e.g., methyl methacrylate-isooctyl acrylate-N-vinyl pyrrolidone), and alkyl acrylate-alkyl methacrylate-hydroxyalkyl methacrylate terpolymers (e.g., isooctyl acrylate-methyl methacrylate-hydroxypropyl methacrylate). Examples of alkyl methacrylate-alkyl-acrylate-N- vinyl pyrrolidone terpolymers and their methods of manufacture are described in U.S. Patent No. 4,584,192
- Preferred organic solvents are those capable of dissolving the polymer and rapidly evaporating after the application of the priming solution to the substrate surface.
- Suitable organic solvents include alkyl alcohols such as, e.g., methanol, ethanol, and isopropyl alcohol.
- Another process for preparing a substrate having polyalkylene imine immobilized thereon involves contacting the substrate with a dilute solution of high molecular weight polyalkylene imine and a low concentration of glutaraldehyde, e.g., an aqueous solution of between about 0.01 and about 0.5% by weight polyethylene imine and between about 0.0001 and about 0.5% by weight glutaraldehyde, optionally followed by contact again with polyalkylene imine, e.g., an aqueous solution of between about 0.01 and about 0.5% by weight polyethylene imine.
- glutaraldehyde e.g., an aqueous solution of between about 0.01 and about 0.5% by weight polyethylene imine.
- the apparatus for removing a biologically active agent may be used in conjunction with other devices.
- the apparatus 10 for removing a biologically active agent is shown in series with an oxygenator 20. Blood flows from the patient to oxygenator 20 via tubing 22 where the blood undergoes oxygenation. The blood then flows to inlet 12 of apparatus 10 for removing a biologically active agent via tubing 24 with the aid of a pump (not shown). As blood flows through substrate 14 the biologically, active agent present in the blood binds with the polyalkylene imine. The blood (minus the bound biologically active agent) flowing through outlet 16 is then returned to the patient via tubing 26.
- the apparatus for removing a biologically active agent 30 is in the form of a syringe. Needle 40 is inserted into a patient so as to contact a supply of blood. Plunger 48 is then pulled so as to create a vacuum, which draws blood from the patient, through needle 40, through substrate 34, and into cylinder 46. As the blood passes over the surface of the substrate 34, a biologically active agent present in the blood binds with the polyethylene imine present on the substrate 34. The blood collected in cylinder 46 may then be analyzed. The apparatus may also be used to remove a biologically active agent from previously drawn blood.
- the apparatus for removing a biologically active agent may also be coupled to a variety of extracorporeal circuits.
- a heparin removal device was prepared using a substrate measuring 2.67 square meters made of precision woven fabric.
- the fabric was woven in a plain weave from 100 micron diameter polyester fiber. It featured 200 micron mesh openings and a 43% open area (Saati PES 200/43).
- the fabric substrate was continuously coated and dried on a web-coating machine using a coating solution containing 2.5% by weight polymer, 15% by weight water, and 82.5% by weight isopropanol.
- the polymer was the reaction product of polyethylene imine (PEI) and an isooctyl acrylate-methyl methacrylate-N-vinyl pyrrolidone terpolymer in which the weight to weight ratios of the respective monomers was 50:40:10.
- the weight to weight ratio of PEI to polymer was 4:1.
- the polymer was prepared as follows. Isooctyl acrylate, methyl methacrylate, and N-vinyl pyrollidone monomers were polymerized as described in Examples 2-8, formulation D of U.S. Patent No.
- terpolymer 4,584,192, to form a terpolymer.
- the terpolymer was then repeatedly washed and distilled to remove any acetone. Once the acetone was removed, the terpolymer was placed in isopropyl alcohol.
- the terpolymer solution and polyethylene imine were then placed in a solution of isopropyl alcohol and water.
- the resulting solution contained 4: 1 polyethylene imine/terpolymer as a 2.5% by weight solids solution in 82.5% by weight isopropyl alcohol and 15% by weight water.
- the coated fabric was wound onto a mandrel to form a 2.5 inch diameter roll and inserted into a tubular acrylic housing with fittings on both ends for 3/8 inch tubing. The device was then tested for its ability to remove heparin from the blood of a 66 kg anesthetized swine.
- the swine was systemically heparinized to maintain an ACT greater than 400 seconds and was placed on a cardiopulmonary bypass (CPB) at normothermic conditions for 60 minutes.
- the swine was then removed from-CPB and its blood was shunted through the heparin removal device from the aorta to the right atrium at a flow rate of approximately 1 liter/minute.
- the blood entered the device at one end, flowed axially through the coated fabric roll, and exited through the opposite end.
- Hemodynamic, hematological, and clinical chemistry parameters were measured pre-CPB, post-CPB, and after connection of the device for 5, 10, 15, 20, and 30 minutes.
- the heparin removal device reduced the circulating heparin from
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98931560A EP0994745A1 (en) | 1997-07-01 | 1998-06-23 | Removal of biologically active agents |
AU81660/98A AU8166098A (en) | 1997-07-01 | 1998-06-23 | Removal of biologically active agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/886,721 US6197289B1 (en) | 1997-07-01 | 1997-07-01 | Removal of biologically active agents |
US08/886,721 | 1997-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999001195A1 true WO1999001195A1 (en) | 1999-01-14 |
Family
ID=25389619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/013145 WO1999001195A1 (en) | 1997-07-01 | 1998-06-23 | Removal of biologically active agents |
Country Status (4)
Country | Link |
---|---|
US (1) | US6197289B1 (en) |
EP (1) | EP0994745A1 (en) |
AU (1) | AU8166098A (en) |
WO (1) | WO1999001195A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1180977A1 (en) * | 1999-06-01 | 2002-02-27 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
US8568448B2 (en) | 1997-12-16 | 2013-10-29 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US9808552B1 (en) | 1997-12-16 | 2017-11-07 | St. Croix Surgical Systems, Llc | Apparatus for closing wounds |
US10231721B2 (en) | 2010-06-24 | 2019-03-19 | St. Croix Surgical Systems, Llc | Failsafe percutaneous wound barrier |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US20030069601A1 (en) * | 1998-12-15 | 2003-04-10 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
RU2378016C2 (en) * | 2004-04-30 | 2010-01-10 | Байофересиз Текнолоджиз, Инк. | Method and system to remove soluble tnfri, tnfr2 and il2 in patients |
US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
WO2011109151A1 (en) | 2010-03-03 | 2011-09-09 | 3M Innovative Properties Company | Ligand guanidinyl functionalized polymers |
US8485986B2 (en) | 2010-06-08 | 2013-07-16 | Merit Medical Systems, Inc. | Biopsy collection device and related methods |
US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
EP3634528B1 (en) | 2017-06-07 | 2023-06-07 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
EP3710076B1 (en) | 2017-11-13 | 2023-12-27 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
EP3746149A4 (en) | 2018-02-01 | 2021-10-27 | Shifamed Holdings, LLC | Intravascular blood pumps and methods of use and manufacture |
US11654275B2 (en) | 2019-07-22 | 2023-05-23 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
WO2021062265A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Intravascular blood pump systems and methods of use and control thereof |
US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3475410A (en) * | 1967-02-08 | 1969-10-28 | Massachusetts Inst Technology | Treatment of a film of cellulose to introduce amino groups and production of non-thrombogenic surfaces on such treated cellulose films |
US4369256A (en) * | 1980-04-18 | 1983-01-18 | Crinos Industria Farmacobiologica S.P.A. | Polyalkylene resins crosslinked with diisocyanate used for selective separation of heparin from other glucosaminoglycanes |
EP0281128A1 (en) * | 1987-03-04 | 1988-09-07 | Slovenska Akademia Vied | Method and preparation for the separation of heparin from blood in vitro |
US4935204A (en) * | 1984-06-16 | 1990-06-19 | B. Braun-Ssc Ag | Process and device for the specific adsorption of heparin |
US5000854A (en) * | 1989-06-14 | 1991-03-19 | The University Of Michigan | Protamine-based filter device for removal of heparin from blood samples |
EP0466178A1 (en) * | 1990-07-13 | 1992-01-15 | Pall Corporation | Method and device for removing heparin |
WO1993014127A1 (en) * | 1992-01-21 | 1993-07-22 | University Of Utah | Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2016962A (en) | 1932-09-27 | 1935-10-08 | Du Pont | Process for producing glucamines and related products |
US2918462A (en) | 1956-01-20 | 1959-12-22 | Ciba Pharm Prod Inc | Process for the preparation of amino-aldehydes |
US3096602A (en) | 1962-01-05 | 1963-07-09 | Dow Chemical Co | Packaging method |
SE306597B (en) | 1964-12-17 | 1968-12-02 | Incentive Ab | |
US3453194A (en) | 1966-08-03 | 1969-07-01 | Dow Corning | Anticoagulant surfaces produced by radiation grafting heparin to a silicone substrate |
US3617344A (en) | 1966-08-05 | 1971-11-02 | Us Health Education & Welfare | Nonthrombogenic plastic surfaces and preparation thereof |
US3475358A (en) | 1967-10-31 | 1969-10-28 | Amicon Corp | Anti-thrombogenic material |
US3639141A (en) | 1968-09-16 | 1972-02-01 | Cordis Corp | Heparinization of plastic |
US3616935A (en) | 1970-02-05 | 1971-11-02 | Dow Chemical Co | Preparation of antithrombogenic surfaces |
US3796634A (en) | 1970-03-19 | 1974-03-12 | Us Health Education & Welfare | Insolubilized biologically active enzymes |
FR2087506A5 (en) | 1970-05-21 | 1971-12-31 | Rhone Poulenc Sa | |
US3846353A (en) | 1970-06-08 | 1974-11-05 | Department Of Health Education | Nonthrombogenic plastic material and method for making the same |
US3853804A (en) | 1970-08-14 | 1974-12-10 | California Inst Of Techn | Ionic block elastomeric polymers |
US3755218A (en) | 1970-08-14 | 1973-08-28 | California Inst Of Techn | Ionically bonded block elastomeric copolymers of a polyquaternary polyurethane and heparin |
US3673612A (en) | 1970-08-28 | 1972-07-04 | Massachusetts Inst Technology | Non-thrombogenic materials and methods for their preparation |
DE2148011C3 (en) | 1970-10-05 | 1978-11-09 | Aminkemi Ab | Process for producing non-thrombogenic plastic surfaces |
US4265827A (en) | 1971-03-08 | 1981-05-05 | Monsanto Company | Catalytic asymmetric hydrogenation |
US3826678A (en) | 1972-06-06 | 1974-07-30 | Atomic Energy Commission | Method for preparation of biocompatible and biofunctional materials and product thereof |
US3947352A (en) | 1974-05-31 | 1976-03-30 | Pedro Cuatrecasas | Polysaccharide matrices for use as adsorbents in affinity chromatography techniques |
GB1495746A (en) | 1974-07-05 | 1977-12-21 | Ciba Geigy Ag | Polymerisation of unsaturated amides |
US4001583A (en) | 1974-10-04 | 1977-01-04 | Barrett M James | Covalently bound biological substances to plastic materials and use in radioassay |
SE400173B (en) | 1975-03-20 | 1978-03-20 | Aminkemi Ab | PROCEDURE FOR STABILIZING A HEPARINIZED SURFACE CONTAINING FOR BLOOD CONTACT RELEASE HEPARIN |
US4102746A (en) | 1975-08-29 | 1978-07-25 | Amerace Corporation | Immobilized proteins |
FR2324664A1 (en) | 1975-09-22 | 1977-04-15 | Rhone Poulenc Ind | POLYURETHANES FOR ITEMS FOR MEDICAL USE |
CA1083508A (en) | 1975-11-13 | 1980-08-12 | Jacques Grange | Supports having lateral chains, process for obtaining such supports, process for the fixation of organic compounds comprising a glucidic residue on said supports, products and reactives from said chimical fixation |
US4048064A (en) | 1976-04-23 | 1977-09-13 | Clark Iii William T | Biocompatible hemoperfusion system |
US4141857A (en) | 1976-04-30 | 1979-02-27 | Uop Inc. | Support matrices for immobilized enzymes |
US4116898A (en) | 1977-01-31 | 1978-09-26 | Becton, Dickinson And Company | Non-thrombogenic articles |
US4349467A (en) | 1977-01-31 | 1982-09-14 | Williams Joel L | Nonthrombogenic articles and method of preparation |
JPS5413694A (en) | 1977-07-01 | 1979-02-01 | Sumitomo Electric Industries | Composite blood vessel prosthesis and method of producing same |
SE425372B (en) | 1977-07-18 | 1982-09-27 | Ird Biomaterial Ab | SET TO HEPARINIZE AN ELECTRICALLY CHARGED SURFACE ON A MEDICAL ARTICLE INTENDED TO CONTACT WITH BLOOD AND MEDICINES TO PERFORM THE SET |
US4239664A (en) | 1978-10-31 | 1980-12-16 | Research Corporation | Anti-thrombogenic PVP-heparin polymer |
GB2041377B (en) | 1979-01-22 | 1983-09-28 | Woodroof Lab Inc | Bio compatible and blood compatible materials and methods |
US4301067A (en) | 1979-06-05 | 1981-11-17 | Kureha Kagaku Kogyo Kabushiki Kaisha | Chitin containing poly-ion complex |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
US4268423A (en) | 1979-11-16 | 1981-05-19 | Uop Inc. | Support matrices for immobilized enzymes |
US4331697A (en) | 1980-09-02 | 1982-05-25 | Teijin Limited | Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative |
CA1160548A (en) | 1980-09-24 | 1984-01-17 | Rolf L. Larsson | Method for detecting proteolytic enzymes in blood |
US4326532A (en) | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
US4424346A (en) | 1981-06-04 | 1984-01-03 | Canadian Patents And Development Ltd. | Derivatives of chitins, chitosans and other polysaccharides |
US4350806A (en) | 1981-09-28 | 1982-09-21 | Akzona Incorporated | Biocompatible copolymers |
US4526714A (en) | 1982-12-13 | 1985-07-02 | Cordis Europa N.V. | Conjugates of anticoagulant and protein |
SE8200751L (en) | 1982-02-09 | 1983-08-10 | Olle Larm | PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS |
SE456347B (en) | 1982-02-09 | 1988-09-26 | Ird Biomaterial Ab | SURFACE MODIFIED SOLID SUBSTRATE AND PROCEDURES FOR PRODUCING THEREOF |
US4737544A (en) | 1982-08-12 | 1988-04-12 | Biospecific Technologies, Inc. | Biospecific polymers |
US5217492A (en) | 1982-09-29 | 1993-06-08 | Bio-Metric Systems, Inc. | Biomolecule attachment to hydrophobic surfaces |
US5258041A (en) | 1982-09-29 | 1993-11-02 | Bio-Metric Systems, Inc. | Method of biomolecule attachment to hydrophobic surfaces |
US4613517A (en) | 1983-04-27 | 1986-09-23 | Becton, Dickinson And Company | Heparinization of plasma treated surfaces |
US4521564A (en) | 1984-02-10 | 1985-06-04 | Warner-Lambert Company | Covalent bonded antithrombogenic polyurethane material |
AU566085B2 (en) | 1984-06-04 | 1987-10-08 | Terumo Kabushiki Kaisha | Medical instrument with surface treatment |
US4600652A (en) | 1985-04-01 | 1986-07-15 | Warner-Lambert Company | Permanently bonded antithrombogenic polyurethane surface |
US4642242A (en) | 1985-04-01 | 1987-02-10 | Becton, Dickinson And Company | Permanently bonded antithrombogenic polyurethane surface |
DE3519011A1 (en) | 1985-05-25 | 1986-11-27 | Behringwerke Ag, 3550 Marburg | METHOD FOR PRODUCING A MATERIAL FOR AFFINITY CHROMATOGRAPHY |
CH665954A5 (en) | 1985-07-08 | 1988-06-30 | Battelle Memorial Institute | SUBSTRATE WITH A SURFACE OF ANTITHROMBOGENIC ACTIVITY. |
JPS6238172A (en) | 1985-08-12 | 1987-02-19 | 株式会社 高研 | Production of anti-thrombotic medical material |
IT1213023B (en) | 1986-01-16 | 1989-12-07 | Rolando Barbucci | MATERIAL ABLE TO ADSORBE STABLY HIGH QUANTITIES OF HEPARIN, AND ITS PREPARATION PROCEDURE. |
US4871357A (en) | 1986-01-21 | 1989-10-03 | Baxter International Inc. | Ionic heparin coating |
US4786556A (en) | 1986-03-24 | 1988-11-22 | Becton, Dickinson And Company | Polymeric articles having enhanced antithrombogenic activity |
US4720512A (en) | 1986-03-24 | 1988-01-19 | Becton, Dickinson And Company | Polymeric articles having enhanced antithrombogenic activity |
CA1305068C (en) | 1986-10-16 | 1992-07-14 | Patrick E. Guire | Biocompatibility of solid surfaces |
US4800016A (en) | 1986-11-24 | 1989-01-24 | The University Of Michigan | Extracorporeal blood de-heparinization system |
US4863611A (en) | 1987-04-30 | 1989-09-05 | Massachusetts Institute Of Technology | Extracorporeal reactors containing immobilized species |
NL8701337A (en) | 1987-06-09 | 1989-01-02 | Sentron V O F | SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS. |
GB8714214D0 (en) | 1987-06-17 | 1987-07-22 | Jack Flooring Co Ltd | Floor panel support system |
US5047020A (en) | 1987-09-14 | 1991-09-10 | Baxter International Inc. | Ionic heparin coating |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US5013717A (en) | 1988-04-18 | 1991-05-07 | Becton, Dickinson And Company | Blood compatible, lubricious article and composition and method therefor |
US5182317A (en) | 1988-06-08 | 1993-01-26 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US4865870A (en) | 1988-07-07 | 1989-09-12 | Becton, Dickinson And Company | Method for rendering a substrate surface antithrombogenic |
US5053048A (en) | 1988-09-22 | 1991-10-01 | Cordis Corporation | Thromboresistant coating |
US5476715A (en) | 1989-10-03 | 1995-12-19 | Fresenius Ag | Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits |
US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5049403A (en) | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5219926A (en) | 1989-12-29 | 1993-06-15 | Berol Nobel Ab | Method of covalently bonding biopolymer to a solid hydrophilic organic polymer |
GB9009570D0 (en) | 1990-04-27 | 1990-06-20 | Biocompatibles Ltd | Antithrombogenic polymers |
WO1992000747A1 (en) | 1990-07-12 | 1992-01-23 | Sterilization Technical Services, Inc. | Anti-thrombogenic and/or anti-microbial composition |
SE466754B (en) | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES |
SE467309B (en) | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | HYDROPHILIZED FIXED SURFACE, PROCEDURE FOR ITS PREPARATION AND AGENTS THEREOF |
SE467308B (en) | 1990-10-22 | 1992-06-29 | Berol Nobel Ab | SOLID SURFACE COATED WITH A HYDROPHILIC SURFACE WITH COVALENTLY BONDED BIOPOLYMERS, SET TO MAKE SUCH A SURFACE AND CONJUGATED THEREOF |
US5132108A (en) | 1990-11-08 | 1992-07-21 | Cordis Corporation | Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents |
US5159050A (en) | 1991-05-09 | 1992-10-27 | Becton, Dickinson And Company | Polyurethane and medical article therefrom |
US5211850A (en) | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
WO1993005825A1 (en) | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Processes for reducing the thrombogenicity of biomaterials |
US5145956A (en) | 1991-12-11 | 1992-09-08 | Glycomed Incorporated | Method for separation of anionic oligosaccharides |
US5391580A (en) | 1992-03-20 | 1995-02-21 | Anatrace Inc. | Poly(sulfone-alpha-olefin) composite permselective membrane article for use in blood oxygenation |
US5308641A (en) * | 1993-01-19 | 1994-05-03 | Medtronic, Inc. | Biocompatibility of solid surfaces |
US5350800A (en) | 1993-01-19 | 1994-09-27 | Medtronic, Inc. | Method for improving the biocompatibility of solid surfaces |
US5416198A (en) | 1993-02-05 | 1995-05-16 | Research Medical, Inc. | Selective sorbent removal system using polycation activated substrates |
US5532311A (en) | 1995-02-01 | 1996-07-02 | Minnesota Mining And Manufacturing Company | Process for modifying surfaces |
US5607475A (en) | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
-
1997
- 1997-07-01 US US08/886,721 patent/US6197289B1/en not_active Expired - Fee Related
-
1998
- 1998-06-23 EP EP98931560A patent/EP0994745A1/en not_active Withdrawn
- 1998-06-23 WO PCT/US1998/013145 patent/WO1999001195A1/en not_active Application Discontinuation
- 1998-06-23 AU AU81660/98A patent/AU8166098A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3475410A (en) * | 1967-02-08 | 1969-10-28 | Massachusetts Inst Technology | Treatment of a film of cellulose to introduce amino groups and production of non-thrombogenic surfaces on such treated cellulose films |
US4369256A (en) * | 1980-04-18 | 1983-01-18 | Crinos Industria Farmacobiologica S.P.A. | Polyalkylene resins crosslinked with diisocyanate used for selective separation of heparin from other glucosaminoglycanes |
US4935204A (en) * | 1984-06-16 | 1990-06-19 | B. Braun-Ssc Ag | Process and device for the specific adsorption of heparin |
EP0281128A1 (en) * | 1987-03-04 | 1988-09-07 | Slovenska Akademia Vied | Method and preparation for the separation of heparin from blood in vitro |
US5000854A (en) * | 1989-06-14 | 1991-03-19 | The University Of Michigan | Protamine-based filter device for removal of heparin from blood samples |
EP0466178A1 (en) * | 1990-07-13 | 1992-01-15 | Pall Corporation | Method and device for removing heparin |
WO1993014127A1 (en) * | 1992-01-21 | 1993-07-22 | University Of Utah | Method and composition for heparin binding using polyaminocations covalently immobilised on polymeric surfaces with polyethylene oxide spacers |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568448B2 (en) | 1997-12-16 | 2013-10-29 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US8652169B2 (en) | 1997-12-16 | 2014-02-18 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US8652168B2 (en) | 1997-12-16 | 2014-02-18 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US9669131B2 (en) | 1997-12-16 | 2017-06-06 | St. Croix Surgical Systems, Llc | Methods of closing wounds |
US9808552B1 (en) | 1997-12-16 | 2017-11-07 | St. Croix Surgical Systems, Llc | Apparatus for closing wounds |
US9839716B1 (en) | 1997-12-16 | 2017-12-12 | St. Croix Surgical Systems, Llc | Methods of closing wounds |
EP1180977A1 (en) * | 1999-06-01 | 2002-02-27 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
EP1180977A4 (en) * | 1999-06-01 | 2007-08-22 | Closys Corp | Clotting cascade initiating apparatus and methods of use |
US10231721B2 (en) | 2010-06-24 | 2019-03-19 | St. Croix Surgical Systems, Llc | Failsafe percutaneous wound barrier |
US10973503B2 (en) | 2010-06-24 | 2021-04-13 | St. Croix Surgical Systems, Llc | Failsafe percutaneous wound barrier |
Also Published As
Publication number | Publication date |
---|---|
US6197289B1 (en) | 2001-03-06 |
EP0994745A1 (en) | 2000-04-26 |
AU8166098A (en) | 1999-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6197289B1 (en) | Removal of biologically active agents | |
US6146771A (en) | Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine | |
US5286449A (en) | Adsorber module for whole blood treatment and an adsorber apparatus containing the adsorber module | |
EP1192959B1 (en) | Antithrombotic surface treating agent and medical apparatus | |
JPH064713B2 (en) | Biocompatible material | |
TWI769171B (en) | Medical device | |
EP0585436A1 (en) | Immobilization of chemical species in crosslinked matrices | |
JP4130316B2 (en) | Leukocyte selective removal filter | |
JPH05500314A (en) | Improved ionic heparin coating | |
KR20040024877A (en) | Polymer for coating leukocyte removal filter material and the filter material | |
EP0625915A1 (en) | Method of producing anti-thrombogenic material and material produced thereby | |
EP0341413B2 (en) | An adsorber module and adsorber apparatus for whole blood treatment | |
CN1177620C (en) | Leukocyte-removing filter material | |
KR20170133341A (en) | Copolymers and medical devices using them, medical membrane modules, and blood purifiers | |
WO2005026224A1 (en) | Separating material | |
JP2000197814A (en) | Leukocyte removing filter and its manufacture | |
EP2261271B1 (en) | Separation material | |
JPH06296686A (en) | Polysulfone hollow yarn membrane for medical purpose | |
US5236592A (en) | Haemocompatible composite material and method of using thereof | |
JP4626005B2 (en) | Hemocompatible composition and medical device coated therewith | |
JP3768009B2 (en) | Blood filter and manufacturing method thereof | |
JP4219041B2 (en) | Leukocyte selective removal material | |
JP2915932B2 (en) | Composite functional porous membrane | |
JP2004129941A (en) | Leukocyte selective removal filter | |
JPS6316969B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998931560 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999507233 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998931560 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998931560 Country of ref document: EP |